[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)


Understand the influence of COVID-19 on the Myasthenia Gravis Treatment Market with our analysts monitoring the situation across the globe.

Global Statistics Representing Myasthenia Gravis Treatment Market Scenario

According to the Myasthenia Gravis Foundation of America, myasthenia gravis is one of the most common primary disorders of neuromuscular transmission. Around 14 to 20 out of every 100,000 people in the United States suffer from myasthenia gravis. While myasthenia gravis can affect people of all ages, it is more common in women under 40 and men older than 60. According to Elsevier, 1,283 New Zealanders are affected by a neuromuscular disorder, amounting to a collective prevalence of 30.25 cases per 100,000.

Growing development of novel drugs such as monoclonal antibodies is driving the growth of the myasthenia gravis treatment market. Moreover, growing awareness regarding treatment and increasing number of clinical facilities are also boosting market growth, globally.

The global myasthenia gravis treatment market was valued at around USD 1,011.1 million in 2017 and is expected to grow at a CAGR of 12.1% during the forecast period.

Intended Audience

  • Government Bodies
  • Hospitals & Clinics & Diagnostic Centres
  • Potential Investors
  • Research and Development Institutes
  • Healthcare Sectors

Segmental Insight

The global myasthenia gravis treatment market can be segmentation by type, treatment, end-user, and region. 

Based on type, the market can be segmented into ocular MG, congenital MG, and transient neonatal MG. The ocular MG segment is expected to account for a prominent market share, owing to the high prevalence of the disease.

Based on treatment, the market can be segmented into medication, surgery, Autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis & intravenous immunoglobulin, and others. Among these, the autologous hematopoietic stem cell transplantation segment is expected to hold a significant market share, owing to the therapy’s cost-effectiveness.

Based on end-user, the market can be segmented into hospitals, clinics, academic research institutes, and others. Among these, the hospitals segment is expected to hold a noteworthy market share during the forecast period.

Regional Analysis

The global myasthenia gravis treatment market has been classified into four key regions, namely North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is expected to hold the largest market share, owing to the increasing number of drug manufacturers and rising awareness about the long-term effects of muscular dystrophy. Moreover, increasing government funding for the treatment of this disease in North America is also favoring market growth. According to National Centers for Advancing Translation Science, in the U.S., around 1 in 500,000 people suffer from disorders each year.

Asia Pacific is expected to be the fastest growing region due to the increasing awareness about neuromuscular disorders and enhancement in healthcare reforms across countries such as Malaysia, India, Indonesia, and China. Apart from this, the increasing geriatric population is supporting market growth on account of the increasing prevalence of the disorder.

Europe accounts for the second largest share in the myasthenia gravis treatment market, owing to the increasing prevalence of autoimmune disorders in the region. For instance, As per Muscular Dystrophy UK, about 15 in every 100,000 people in the U.K. are affected by myasthenia gravis.

The Middle East region is projected to witness steady growth, owing to the extensive advancement of healthcare infrastructure and growing R&D activities in the healthcare sector.

Key Developments

  • In 2018, Teva Pharmaceutical Industries Ltd. launched the generic version of Syprine capsules, 250 mg, in the U.S.
  • In 2015, Fresenius Kabi introduced the anti-infective Moxifloxacin Injection 400 mg per 250 mL in Freeflex bags.

Report Inclusions

  • Historical inferences, findings & analysis of the market for the duration of 2016 to 2018
  • Projections and performance forecast analysis for the duration of 2019 to 2026
  • Production and consumption point-of-view (POV) analysis
  • Market driver, restraint and opportunity analysis to define market dynamics, covering industry, regulatory, innovation, technological, and pricing trends
  • Comprehensive competitive landscape mapping with recent developments, covering market leadership, competency, sustainability, and future prospects

Key Players

Some of the key players in the global myasthenia gravis treatment market are Valeant Pharmaceuticals International, Novartis Pharmaceuticals Corporation, Apotex Corporation, Teva Pharmaceutical Industries Ltd., RPG Life Sciences, Cipla, F. Hoffmann Roche La Ltd., Bristol-Myers Squibb Company, Biogen Inc., AbbVie Inc., GlaxoSmithKline plc, and Fresenius Kabi.

Myasthenia Gravis Treatment Market Segmentation

By Type

  • Ocular MG
  • Congenital MG
  • Transient Neonatal MG

By Treatment

  • Medication
  • Surgery
  • Autologous Hematopoietic Stem Cell Transplantation (HSCT)
  • Plasmapheresis & Intravenous Immunoglobulin
  • Others

By End-User

  • Hospitals
  • Clinics
  • Academic Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific

Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports